Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals orders, deals and press releases
594 filed, newest first. Page 11 of 12.
May 2010
Apr 2010
29 Apr · Business
Press release dated April 29, 2010, titled "Glenmark launches Prasugrel for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Apr · Business
Press release dated April 26, 2010, titled "Glenmark Generics receives USFDA approval for Norethindrone tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 12, 2010, titled "Glenmark Generics announces the settlement of Paragraph IV litigation with GSK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 07, 2010, titled "Glenmark Generics receives UK-MA approval for Ropinirole film-coated tablets and to distribute Lercanidipine Hydrochloride film-coated tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2010, titled "Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
31 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 31, 2010, titled "Glenmark Generics announced New Drug Applications for Oxycodone Hydrochloride Capsules and Liquid Solution". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 26, 2010, titled "Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.18 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 18, 2010, titled " Glenmark Generics receives approval from the USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release vide its letter dated March 02, 2010, titled " Glenmark Generics receives approval from the USFDA for Ropinirole Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
29 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 29, 2010, titled "Glenmark's consolidated revenue increases by 10% to Rs. 6416.85 Mn for Q3-FY'10. Consolidated Net Profit increases by 15.5% at Rs.940.73 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the Third quarter of the Financial Year 2009-10 ended December 31, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 22, 2010, titled "Glenmark Generics Ltd granted tentative approval by US-FDA for Trandolapril and Verapamil Hydrochloride extended-release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
24 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 24, 2009, titled "Glenmark Generics Ltd receives Tentative Approval from USFDA for Pramipexole Dihydrochloride tablets and Atomoxetine Hydrochloride capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 16, 2009, titled "Glenmark in-licenses its first product from Stratpharma AG, Switzerland for scar management therapy in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 16, 2009, titled "Glenmark Pharmaceuticals outlicenses a specialty pharmaceutical product to medicis pharmaceutical for the North America Region". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 16, 2009, titled "Glenmark Generics announces the settlement of Para IV litigations with Medicis Pharmaceutical Corporation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 14, 2009, titled "Glenmark Generics receives ANDA approval from US-FDA for Ciclopirox Olamine Cream". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
29 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 29, 2009, titled "Glenmark's consolidated revenue increases by 5% to Rs. 5903.26 Mn for Q2-FY'10. Consolidated Net Profit at Rs. 808.85 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the second quarter of the Financial Year 2009-10 ended September 30, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 27, 2009, titled "Glenmark Generics Europe announces the launch of its first Four Products for the UK market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2009
18 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "The Committee of Directors of Glenmark Pharmaceuticals Limited (the "Company") has at its meeting held on September 18, 2009 approved the allotment of 18,712,935 equity shares of face value of Re. 1 pursuant to the qualified institutions placement of its equity shares and authorized the Company to do such acts necessary to effect the allotment and listing of the equity shares".18 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 18, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Verapamil SR tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Committee of Directors of Glenmark Pharmaceuticals Ltd. (the Company) has at its meeting held on September 14, 2009 determined September 14, 2009 to be the issue closing date and Rs. 221 per Equity Share to be the issue price pursuant to the qualified institutions placement of the equity shares. The Committee has also approved the Placement Document in respect of the equity shares proposed to be issued as aforesaid. The Company proposes to issue 18,712,935 equity shares of face value of Re. 1 each to raise aggregate proceeds of Rs. 4,135.56 million and net proceeds, after deduction of issue expenses, of Rs. 4038.19 million. The outstanding paid up capital of the Company pursuant to the issue shall be Rs. 269,581,053".11 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "The Committee of Directors of Glenmark Pharmaceuticals Limited (the "Company") has at its meeting held on September 10, 2009, pursuant to the authorization given by the shareholders given under Section 81(1A) and other applicable provisions of the Companies Act, 1956, decided to make an issuance of equity shares of face value of Re.1 each of the Company to Qualified Institutional Buyers and for this purpose, to open the issue. The Committee has also approved the Preliminary Placement Document in respect of the equity shares proposed to be issued as aforesaid".
Aug 2009
19 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 19, 2009, titled "Forest/Glenmark announces Phase IIb Study Results for Oglemilast in Chronic Obstructive Pulmonary Disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 18, 2009, titled "Glenmark Confirms Patent Challenge on Atovaquone & Proguanil Hydrochloride tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 10, 2009, titled "Crofelemer dose selection stage of Phase III trials completed. Molecule progresses to final stage of Phase III trials in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
31 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 31, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Ointment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 27, 2009, titled "Glenmark's Consolidated revenue increases by 18% to Rs. 5,436.88 million for Q1-FY'10. Consolidated Net Profit at Rs 534.55 million for the quarter". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the First quarter ended June 30, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 10, 2009, titled "Glenmark to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
27 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 26, 2009, titled "Glenmark's Consolidated revenue increases by 6% to Rs. 21,215.39 Mn; Consolidated Net Profit was at 1934.73 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the Fourth quarter of the Financial Year 2008-09 Ended March 31, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 25, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Cream". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 24, 2009 titled "Glenmark's novel molecule for Diabetes, Melogliptin to enter phase III trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 01, 2009, titled "Glenmark receives ANDA approval from U.S. FDA for Hydralazine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
27 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding press release informing that the Company's subsidiary has received tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe. In this regard Company has submitted a copy of press release dated April 27, 2009, titled "Glenmark receives tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 13, 2009, titled "Glenmark's molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
4 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 04, 2009, titled "Glenmark receives approval from the U.S. FDA for Lithium Carbonate Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the Management Discussion & Analysis for the 3rd quarter of the Financial Year 2008-09 ended December 31, 2008 and copy of press release dated January 27, 2009, titled "Glenmark's consolidated revenue at Rs.5813.89 mn, declines by 14.42%; Net Profit at Rs.814.32 mn, declines by 70.91% for Q3 FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 23, 2009, titled "Glenmark's molecule for Osteoarthritic and Neuropathic Pain, GRC 15300, to enter Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 16, 2009, titled "Glenmark to market Levetiracetam tablets for the US market. U.S. FDA grants Day 1 ANDA approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
22 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 22, 2008, titled "Glenmark expects launch of Crofelemer in ROW Countries (Developing Economies) by 2010". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 17, 2008, titled "Glenmark Confirms Patent Challenge of Fluticasone Lotion". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 11, 2008, titled "SCRIP, the leading pharmaceutical magazine in the world Crowns Glenmark as the "Best Pharma Company in the World- SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
21 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 21, 2008, titled "Glenmark receives approval for Ranitidine Tablets USP from the U.S. FDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 20, 2008, titled "Glenmark Launches Azathioprine Tablets in the U.S. Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 10, 2008, titled "Glenmark Generics Ltd enhances Pain Management Portfolio for the U.S. Market; Launches Morphine Sulfate Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 06, 2008, titled "Glenmark Generics Limited launches its first product in the United Kingdom; Launches Perindopril, an ACE inhibitor for symptomatic heart failure". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
27 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 27, 2008, titled "Glenmark posts consolidated revenue growth of 49.30% and Net profit growth of 56.21% for Q2 FY09; Consolidated revenue at Rs. 5597.19 Mn and Net Profit at Rs. 1173.60 Mn". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 24, 2008, titled "Further clinical trials in Osteoarthritis pain suspended for GRC 6211". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 10, 2008, titled "Phase II-b trials for Oglemilast(GRC 3886) in Asthma initiated". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.